Oxford BioMedica has been granted a patent for a nucleic acid sequence that includes a binding site for an RNA-binding protein (TRAP) linked to a nucleotide of interest. This sequence is designed to repress translation in viral vector production cells, enhancing the efficiency of vector production. GlobalData’s report on Oxford BioMedica gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Oxford BioMedica, was a key innovation area identified from patents. Oxford BioMedica's grant share as of July 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Nucleic acid sequence for repressing translation in viral vectors
The granted patent US12054735B2 presents a novel nucleic acid sequence designed to regulate the translation of a nucleotide of interest (NOI) through the interaction with a specific RNA-binding protein (RBP), namely the tryptophan RNA-binding attenuation protein (TRAP). The claims detail that the RBP binding site is operably linked to the NOI and is capable of repressing its translation in viral vector production cells. The patent specifies various configurations of the TRAP binding site, including multiple repeats of the sequence RAGN2-3, with particular emphasis on the number of repeats, which can range from one to eleven. Additionally, the NOI may encode therapeutic proteins, enhancing the potential applications of this technology in gene therapy and related fields.
The patent further extends its claims to include viral vectors that incorporate the described nucleic acid sequence, with options for various types of viral vectors such as retroviral, adenoviral, and lentiviral vectors. It also outlines methods for identifying nucleic acid binding sites and proteins by analyzing the expression of the NOI in cells containing the nucleic acid sequence and the RBP. Furthermore, a method for repressing the translation of the NOI in viral vector production cells is described, which involves introducing the nucleic acid sequence and the RBP-encoding sequence into the cells. This innovative approach could significantly impact the efficiency and control of therapeutic protein production in viral vector systems.
To know more about GlobalData’s detailed insights on Oxford BioMedica, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
